Braveheart Bio jumps 68% in trading debut after $383M IPO

Braveheart Bio hit Nasdaq on August 6 like a company that already had something to prove. Shares opened at $30.20, a 68% premium to the $18 IPO price, vaulting the pre-revenue cardiovascular biotech to a market capitalization north of $2 billion before most traders had finished their morning coffee.

The company raised $382.5 million by selling 21.25 million shares, pricing above a marketed range of $15 to $17. For a firm with no approved products and no revenue, that kind of reception tells you something about where investor appetite is right now.

A bet on hearts, not revenue

Braveheart Bio’s entire investment thesis rests on a single drug candidate: BHB-1893, an oral cardiac myosin inhibitor licensed from Jiangsu Hengrui Pharmaceuticals. The compound targets hypertrophic cardiomyopathy, a condition where the heart muscle becomes abnormally thick, making it harder for the heart to pump blood.

The company plans to use IPO proceeds to fund global Phase 3 trials. The obstructive form of the disease, known as oHCM, is slated for trial initiation in late 2026. Non-obstructive hypertrophic cardiomyopathy trials are expected to follow in early 2027.

Hypertrophic cardiomyopathy affects an estimated 1 in 500 people globally, and current treatment options remain limited. Bristol-Myers Squibb’s mavacamten, sold as Camzyos, was the first cardiac myosin inhibitor approved for oHCM. Non-obstructive HCM currently has no approved cardiac myosin inhibitor therapy, which makes it the kind of white space that biotech investors love to price in early.

The underwriter roster and investor backing

Goldman Sachs and Jefferies served as lead underwriters, with TD Cowen, Stifel, and Cantor rounding out the syndicate. The oversubscription pushed pricing above the initial range.

Andreessen Horowitz (a16z) is among Braveheart Bio’s backers. Underwriters also secured a 30-day option to purchase an additional 3.1875 million shares, which if exercised in full would bring total IPO proceeds to roughly $440 million.

The company filed its initial S-1 registration statement on July 15, 2026. CEO Travis Murdoch led the roadshow that converted investor interest into a deal that priced above its marketed range in just three weeks.

Biotech IPO window cracks wide open

Braveheart Bio’s debut didn’t happen in isolation. The same week saw multiple biotech companies attempting public listings, with aggregate target proceeds exceeding $1 billion.

For Braveheart Bio specifically, a 68% first-day pop is a double-edged sword. On one hand, it validates investor demand and gives the company a strong currency for potential future fundraising or partnerships. On the other, it suggests the deal may have been underpriced — the difference between raising at $18 and what the market was clearly willing to pay at $30 amounts to hundreds of millions of dollars in dilution that existing shareholders absorbed unnecessarily.

With a $2.13 billion to $2.2 billion market cap and zero revenue, the stock is trading entirely on the promise of Phase 3 data that won’t arrive for at least a year.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.